{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:45:07Z","timestamp":1790372707787,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Fapesp","doi-asserted-by":"crossref","award":["2019\/ 15802-1"],"award-info":[{"award-number":["2019\/ 15802-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018217","name":"Universidade Federal De S\u00e3o Paulo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018217","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Hypothesis<\/jats:title>\n                    <jats:p>\n                      Genitourinary syndrome of menopause is a chronic and high prevalent condition with a substantial negative impact in women's\u00a0quality of life and\u00a0vaginal health. The prevalence of GSMis even higher among breast cancer survivors receiving endocrine adjuvant therapy.\u00a0This study aimed to evaluate the efficacy and safety of CO\n                      <jats:sub>2<\/jats:sub>\n                      laser (CO\n                      <jats:sub>2<\/jats:sub>\n                      L), radiofrequency (RF), and promestriene in treating genitourinary syndrome of menopause (GSM) in this population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A multi-arm randomized clinical trial enrolled postmenopausal women with breast cancer undergoing endocrine adjuvant therapy. Participants were randomized to receive CO\n                      <jats:sub>2<\/jats:sub>\n                      L, RF, or promestriene treatment. The study assessed before, 4, and 10\u00a0months after treatment GSM symptoms, Vaginal Health Index (VHI), sexual function, and urinary symptoms using validated tools. Statistical analysis was performed to compare treatment outcomes and adverse events.\n                    <\/jats:p>\n                    <jats:p>The intensity and frequency of GSM signs and symptoms before and after the proposed therapies were evaluated, along with their impact on health-related quality of life, patient satisfaction, and the presence of adverse events related to the treatments, during the 10 months follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-eight women completed the treatment and the 10-month follow-up (21 CO\n                      <jats:sub>2<\/jats:sub>\n                      L, 19 RF, 18 promestriene). The groups were similar regarding the intensity of vaginal health symptoms and demographic parameters. All treatment groups showed significant improvement in GSM symptoms, VHI, and sexual function. Urinary symptoms were reduced in the CO\n                      <jats:sub>2<\/jats:sub>\n                      L and RF groups, with sustained improvement at the 10-month follow-up. Adverse events were mild and well tolerated, with no serious complications reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      CO\n                      <jats:sub>2<\/jats:sub>\n                      L, RF, and promestriene demonstrated efficacy in improving GSM symptoms, VHI, and sexual function in breast cancer survivors receiving adjuvant endocrine therapy. These treatments offer safe and effective alternatives for managing GSM in this population, with potential benefits for health-related quality of life and treatment adherence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00192-026-06784-4","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:12:45Z","timestamp":1784193165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Laser, radiofrequency, and promestriene in the treatment of genitourinary syndrome of menopause in breast cancer survivors: randomized clinical trial"],"prefix":"10.1007","author":[{"given":"Chayane","family":"Dedonatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria Homem de Mello","family":"Bianchi-Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita de Cassia de Maio","family":"Dardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marair Gracio Ferreira","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LARF- Study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G C","family":"Cantarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R B","family":"Vanzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M F R","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C","family":"Nazario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z I K","family":"Jarmy di \u2013 Bella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa Teresinha","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"9","key":"6784_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/GME.0000000000001609","volume":"27","author":"The NAMS 2020 GSM Position Statement Editorial Panel","year":"2020","unstructured":"The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976\u201392. https:\/\/doi.org\/10.1097\/GME.0000000000001609.","journal-title":"Menopause"},{"issue":"10","key":"6784_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11934-018-0831-y","volume":"19","author":"A Rabley","year":"2018","unstructured":"Rabley A, O\u2019Shea T, Terry R, Byun S, Louis Moy M. Laser therapy for genitourinary syndrome of menopause. Curr Urol Rep. 2018;19(10):83. https:\/\/doi.org\/10.1007\/s11934-018-0831-y","journal-title":"Curr Urol Rep"},{"issue":"1","key":"6784_CR3","doi-asserted-by":"publisher","first-page":"26.e1","DOI":"10.1016\/j.ajog.2010.08.035","volume":"204","author":"J Baumgart","year":"2011","unstructured":"Baumgart J, Nilsson K, Stavreus-Evers A, Kask K, Villman K, Lindman H, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e1-26.e267. https:\/\/doi.org\/10.1016\/j.ajog.2010.08.035","journal-title":"Am J Obstet Gynecol"},{"key":"6784_CR4","unstructured":"Globocan (2020) New global cancer data. GLOBOCAN:. Available from: https:\/\/www.uicc.org\/news\/globocan-2020-new-global-cancer-data (acessed March, 2021)."},{"issue":"1","key":"6784_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1023\/a:1020299707510","volume":"76","author":"WF Anderson","year":"2002","unstructured":"Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 2002;76(1):27\u201336. https:\/\/doi.org\/10.1023\/a:1020299707510","journal-title":"Breast Cancer Res Treat"},{"key":"6784_CR6","unstructured":"Pompei LM, Fernandes CE, Melo NR. Promestrieno no tratamento da atrofia vulvovaginal: revis\u00e3o sistem\u00e1tica. Femina, 2010:38(7):359:365. Available from https:\/\/docs.bvsalud.org\/upload\/S\/0100-7254\/20201\/v38n7\/a1524.pdfdocs.bvsalud.org"},{"issue":"3","key":"6784_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","volume":"232","author":"ME Beste","year":"2025","unstructured":"Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. Am J Obstet Gynecol. 2025;232(3):262\u2013270.e1. https:\/\/doi.org\/10.1016\/j.ajog.2024.10.054","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"6784_CR8","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/GME.0000000000001333","volume":"26","author":"CA Politano","year":"2019","unstructured":"Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause. 2019;26(8):833\u201340. https:\/\/doi.org\/10.1097\/GME.0000000000001333.","journal-title":"Menopause"},{"issue":"4","key":"6784_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/13697137.2014.899347","volume":"17","author":"S Salvatore","year":"2014","unstructured":"Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17(4):363\u20139. https:\/\/doi.org\/10.3109\/13697137.2014.899347.","journal-title":"Climacteric"},{"key":"6784_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2023.1002","volume":"78","author":"ACA Sarmento","year":"2023","unstructured":"Sarmento ACA, Fernandes FS, Maia RR, de Ara\u00fajo Santos Camargo JD, de Oliveira Crispim JC, Eleut\u00e9rio J\u00fanior J, et al. Microablative fractional radiofrequency for sexual dysfunction and vaginal trophism: a randomized clinical trial. Clinics. 2023;78:100293. https:\/\/doi.org\/10.1016\/j.clinsp.2023.1002.","journal-title":"Clinics"},{"issue":"1","key":"6784_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/GME.0000000000001416","volume":"27","author":"MFR Paraiso","year":"2020","unstructured":"Paraiso MFR, Ferrando CA, Sokol ER, Rardin CR, Matthews CA, Karram MM, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial. Menopause. 2020;27(1):50\u20136. https:\/\/doi.org\/10.1097\/GME.0000000000001416.","journal-title":"Menopause"},{"issue":"3","key":"6784_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jsxm.2021.12.010","volume":"19","author":"M Filippini","year":"2022","unstructured":"Filippini M, Porcari I, Ruffolo AF, Casiraghi A, Farinelli M, Uccella S, et al. CO2-laser therapy and genitourinary syndrome of menopause: a systematic review and meta-analysis. J Sex Med. 2022;19(3):452\u201370. https:\/\/doi.org\/10.1016\/j.jsxm.2021.12.010","journal-title":"J Sex Med"},{"issue":"12","key":"6784_CR13","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1089\/photob.2023.0113","volume":"41","author":"CD de Oliveira","year":"2023","unstructured":"de Oliveira CD, de Mello Bianchi AMH, Campos MLP, Nogueira MCC, Sartori MGF, de G\u00f3is Speck NM. Women with genitourinary syndrome of menopause treated with vaginal estriol, microablative fractional CO2 laser and microablative fractional radiofrequency: a randomized pilot study. Photobiomodul Photomed Laser Surg. 2023;41(12):718\u201324. https:\/\/doi.org\/10.1089\/photob.2023.0113","journal-title":"Photobiomodul Photomed Laser Surg"},{"issue":"1","key":"6784_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/medicina60010080","volume":"60","author":"MLP Campos","year":"2023","unstructured":"Campos MLP, Bianchi-Ferraro AMHM, de Oliveira CD, Nogueira MCC, Sartori MGF, Fusco I, et al. Fractional CO2 laser, radiofrequency and topical estrogen for treating genitourinary syndrome of menopause: a pilot study evaluating the vulvar vestibule. Medicina (Kaunas). 2023;60(1):80. https:\/\/doi.org\/10.3390\/medicina60010080","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"6784_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/aogs.14353","volume":"101","author":"OE Mortensen","year":"2022","unstructured":"Mortensen OE, Christensen SE, L\u00f8kkegaard E. The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: a state-of-the-art review. Acta Obstet Gynecol Scand. 2022;101(6):657\u201392. https:\/\/doi.org\/10.1111\/aogs.14353","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"6784_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/009262300278597","volume":"26","author":"R Rosen","year":"2000","unstructured":"Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191\u2013208. https:\/\/doi.org\/10.1080\/009262300278597","journal-title":"J Sex Marital Ther"},{"issue":"8","key":"6784_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1590\/S0100-72032007000800003","volume":"29","author":"APL Leite","year":"2007","unstructured":"Leite APL, Moura EA, Campos AAS, Mattar R, Souza E, Caano L. Validation of the female sexual function index in Brazilian pregnant women. Rev Bras Ginecol Obstet. 2007;29(8):396\u2013401. https:\/\/doi.org\/10.1590\/S0100-72032007000800003","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"10","key":"6784_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00192-009-0916-8","volume":"20","author":"CC Souza","year":"2009","unstructured":"Souza CC, Rodrigues AM, Ferreira CE, Fonseca ES, di Bella ZI, Gir\u00e3o MJ, et al. Portuguese validation of the Urinary Incontinence-Specific Quality-of-Life Instrument: I-QOL. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20(10):1183\u20139. https:\/\/doi.org\/10.1007\/s00192-009-0916-8","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"12","key":"6784_CR19","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/GME.0000000000002274","volume":"30","author":"MFR Fernandes","year":"2023","unstructured":"Fernandes MFR, Bianchi-Ferraro AMHM, Sartori MGF, J\u00e1rmy Di Bella ZIK, Cantarelli GC, Dedonatto C, et al. CO 2 laser, radiofrequency, and promestriene in the treatment of genitourinary syndrome of menopause in breast cancer survivors: a histomorphometric evaluation of the vulvar vestibule. Menopause. 2023;30(12):1213\u201320. https:\/\/doi.org\/10.1097\/GME.0000000000002274.","journal-title":"Menopause"},{"issue":"10","key":"6784_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/CAD.0b013e328365288e","volume":"24","author":"L Del Pup","year":"2013","unstructured":"Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, et al. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anti-cancer Drugs. 2013;24(10):989\u201398. https:\/\/doi.org\/10.1097\/CAD.0b013e328365288e.","journal-title":"Anti-cancer Drugs"},{"issue":"6","key":"6784_CR21","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/GME.0000000000001121","volume":"25","author":"SS Faubion","year":"2018","unstructured":"Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women\u2019s Sexual Health. Menopause. 2018;25(6):596\u2013608. https:\/\/doi.org\/10.1097\/GME.0000000000001121.","journal-title":"Menopause"},{"issue":"6","key":"6784_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/GME.0000000000001053","volume":"25","author":"T Pagano","year":"2018","unstructured":"Pagano T, De Rosa P, Vallone R, Schettini F, Arpino G, Giuliano M, et al. Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause (New York, NY). 2018;25(6):657\u201362. https:\/\/doi.org\/10.1097\/GME.0000000000001053.","journal-title":"Menopause (New York, N.Y.)"},{"issue":"5","key":"6784_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/13697137.2016.1212006","volume":"19","author":"S Athanasiou","year":"2016","unstructured":"Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME, et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric:J Int Menopause Soc. 2016;19(5):512\u20138. https:\/\/doi.org\/10.1080\/13697137.2016.1212006","journal-title":"Climacteric:J Int Menopause Soc"},{"key":"6784_CR24","doi-asserted-by":"publisher","first-page":"e1750","DOI":"10.6061\/clinics\/2020\/e1750","volume":"75","author":"AC Sarmento","year":"2020","unstructured":"Sarmento AC, Fernandes FS, Marconi C, Giraldo PC, Eleut\u00e9rio-J\u00fanior J, Crispim JC, et al. Impact of microablative fractional radiofrequency on the vaginal health, microbiota, and cellularity of postmenopausal women. Clinics (Sao Paulo, Brazil). 2020;75:e1750. https:\/\/doi.org\/10.6061\/clinics\/2020\/e1750","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"4","key":"6784_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00404-016-4118-6","volume":"294","author":"A Pieralli","year":"2016","unstructured":"Pieralli A, Fallani MG, Becorpi A, Bianchi C, Corioni S, Longinotti M, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841\u20136. https:\/\/doi.org\/10.1007\/s00404-016-4118-6","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"6784_CR26","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1016\/j.clbc.2021.01.006","volume":"21","author":"S Salvatore","year":"2021","unstructured":"Salvatore S, Nappi RE, Casiraghi A, Ruffolo AF, Degliuomini R, Parma M, et al. Microablative fractional CO2 laser for vulvovaginal atrophy in women with a history of breast cancer: a pilot study at 4-week follow-up. Clin Breast Cancer. 2021;21(5):e539\u201346. https:\/\/doi.org\/10.1016\/j.clbc.2021.01.006.","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"6784_CR27","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1007\/s00192-022-05091-y","volume":"33","author":"AS Seki","year":"2022","unstructured":"Seki AS, Bianchi-Ferraro AMHM, Fonseca ESM, Sartori MGF, Gir\u00e3o MJBC, Jarmy-Di Bella ZIK. CO2 laser and radiofrequency compared to a sham control group in treatment of stress urinary incontinence (LARF study arm 3). A randomized controlled trial. Int Urogynecol J. 2022;33(12):3535\u201342. https:\/\/doi.org\/10.1007\/s00192-022-05091-y.","journal-title":"Int Urogynecol J"},{"issue":"2","key":"6784_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/gme.0b013e31826560da","volume":"20","author":"J Baumgart","year":"2013","unstructured":"Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162\u20138. https:\/\/doi.org\/10.1097\/gme.0b013e31826560da.","journal-title":"Menopause"},{"issue":"4","key":"6784_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3390\/ph16040550","volume":"16","author":"L Merlino","year":"2023","unstructured":"Merlino L, D\u2019Ovidio G, Matys V, Piccioni MG, Porpora MG, Senatori R, et al. Therapeutic choices for Genitourinary Syndrome of Menopause (GSM) in Breast cancer survivors: a systematic review and update. Pharmaceuticals (Basel, Switzerland). 2023;16(4):550. https:\/\/doi.org\/10.3390\/ph16040550","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"2","key":"6784_CR30","doi-asserted-by":"publisher","first-page":"e2255697","DOI":"10.1001\/jamanetworkopen.2022.55697","volume":"6","author":"E Mension","year":"2023","unstructured":"Mension E, Alonso I, Angl\u00e8s-Acedo S, Ros C, Otero J, Villarino \u00c1, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open. 2023;6(2):e2255697. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55697","journal-title":"JAMA Netw Open"},{"issue":"9","key":"6784_CR31","doi-asserted-by":"publisher","first-page":"e2232563","DOI":"10.1001\/jamanetworkopen.2022.32563","volume":"5","author":"YC Jang","year":"2022","unstructured":"Jang YC, Leung CY, Huang HL. Comparison of severity of genitourinary syndrome of menopause symptoms after carbon dioxide laser vs vaginal estrogen therapy: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(9):e2232563. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.32563","journal-title":"JAMA Netw Open"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06784-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-026-06784-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-026-06784-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:12:50Z","timestamp":1784193170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-026-06784-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":31,"alternative-id":["6784"],"URL":"https:\/\/doi.org\/10.1007\/s00192-026-06784-4","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was previously published as part of the master\u2019s dissertation of Chayane MD Dedonatto, presented to the Federal University of S\u00e3o Paulo in 2023. It was also presented at the IUGA Meeting in 2023, as an oral presentation.","order":1,"name":"Ethics","label":"Previously Published\/Presented","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}